摘要
近年来,我国耐碳青霉烯类肺炎克雷伯菌(arbapenem-resistant klebsiella pneumonia,CRKP)的检出率逐年升高,其临床治疗手段尚不明确,耐药机制复杂。因此,通过降低耐药菌感染的风险,进而减少耐药肺炎克雷伯菌感染,可以节省医疗资源且易于实行。基于上述原因,对肺炎克雷伯菌(klebsiella pneumonia,KP)产生耐药的机制、感染的风险因素进展进行了概述。
In recent years,the detection rate of carbapenem-resistant klebsiella pneumonia(CRKP)in China has been increasing year by year,and its clinical treatment methods are still unclear,and the mechanism of drug resistance is complex.Therefore,by reducing the risk factors for drug-resistant bacterial infections,and thus drug-resistant Klebsiella pneumoniae infections,medical resources can be saved and easy to implement.Based on the above reasons,this article summarizes the mechanism of drug resistance in Klebsiella pneumoniae(KP)and the progression of risk factors for infection.
作者
章博宁
史鹏
Zhang Boning;Shi Peng(School of Clinical Medicine,Changchun University of Traditional Chinese Medicine,Changchun,Jilin,130117;Jilin Provincial People’s Hospital,Changchun,Jilin,130012)
出处
《科技与健康》
2024年第3期39-41,共3页
Technology and Health
关键词
耐碳青霉烯
肺炎克雷伯菌
风险因素
耐药菌
Carbapenem-resistant
Klebsiella pneumoniae
risk factors
Drug-resistant bacteria
作者简介
章博宁(1998—),男,长春中医药大学临床医学院硕士研究生,研究方向为呼吸系统疾病;史鹏(1978—),女,硕士,吉林省人民医院副主任医师,研究方向为呼吸系统疾病。
